These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23760859)

  • 1. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.
    Xie J; Tworoger SS; Franke AA; Terry KL; Rice MS; Rosner BA; Willett WC; Hankinson SE; Eliassen AH
    Breast Cancer Res Treat; 2013 Jun; 139(3):801-9. PubMed ID: 23760859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
    Piller R; Chang-Claude J; Linseisen J
    Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
    Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
    Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
    Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
    Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating enterolactone and risk of breast cancer: a prospective study in New York.
    Zeleniuch-Jacquotte A; Adlercreutz H; Shore RE; Koenig KL; Kato I; Arslan AA; Toniolo P
    Br J Cancer; 2004 Jul; 91(1):99-105. PubMed ID: 15226762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
    Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
    Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
    Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans.
    Piller R; Verla-Tebit E; Wang-Gohrke S; Linseisen J; Chang-Claude J
    J Nutr; 2006 Jun; 136(6):1596-603. PubMed ID: 16702327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
    Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
    J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-diagnostic plasma enterolactone concentrations and breast cancer prognosis among postmenopausal women - The Danish Diet, Cancer and Health cohort.
    Kyrø C; Hansen L; Frederiksen K; Nørskov NP; Bach Knudsen KE; Eriksen AK; Holm M; Tjønneland A; Olsen A
    Clin Nutr; 2018 Dec; 37(6 Pt A):2217-2225. PubMed ID: 29154112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of enterolactone and percentage mammographic density among postmenopausal women.
    Stuedal A; Gram IT; Bremnes Y; Adlercreutz H; Veierød MB; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2154-9. PubMed ID: 16172225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediagnostic plasma enterolactone levels and mortality among women with breast cancer.
    Olsen A; Christensen J; Knudsen KE; Johnsen NF; Overvad K; Tjønneland A
    Breast Cancer Res Treat; 2011 Aug; 128(3):883-9. PubMed ID: 21340481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
    Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An incident case-referent study on plasma enterolactone and breast cancer risk.
    Hultén K; Winkvist A; Lenner P; Johansson R; Adlercreutz H; Hallmans G
    Eur J Nutr; 2002 Aug; 41(4):168-76. PubMed ID: 12242585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status.
    Touillaud MS; Thiébaut AC; Fournier A; Niravong M; Boutron-Ruault MC; Clavel-Chapelon F
    J Natl Cancer Inst; 2007 Mar; 99(6):475-86. PubMed ID: 17374837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
    Tamimi RM; Byrne C; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2007 Aug; 99(15):1178-87. PubMed ID: 17652278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis.
    Seibold P; Vrieling A; Johnson TS; Buck K; Behrens S; Kaaks R; Linseisen J; Obi N; Heinz J; Flesch-Janys D; Chang-Claude J
    Int J Cancer; 2014 Aug; 135(4):923-33. PubMed ID: 24436155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes.
    Sonestedt E; Ivarsson MI; Harlid S; Ericson U; Gullberg B; Carlson J; Olsson H; Adlercreutz H; Wirfält E
    J Nutr; 2009 May; 139(5):993-1001. PubMed ID: 19321582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
    Stattin P; Adlercreutz H; Tenkanen L; Jellum E; Lumme S; Hallmans G; Harvei S; Teppo L; Stumpf K; Luostarinen T; Lehtinen M; Dillner J; Hakama M
    Int J Cancer; 2002 May; 99(1):124-9. PubMed ID: 11948503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating enterolactone and risk of endometrial cancer.
    Zeleniuch-Jacquotte A; Lundin E; Micheli A; Koenig KL; Lenner P; Muti P; Shore RE; Johansson I; Krogh V; Lukanova A; Stattin P; Afanasyeva Y; Rinaldi S; Arslan AA; Kaaks R; Berrino F; Hallmans G; Toniolo P; Adlercreutz H
    Int J Cancer; 2006 Nov; 119(10):2376-81. PubMed ID: 16929490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.